Profil
NORMAN BARTON, M.D., PH.D., currently Executive Vice President and Chief Medical Officer of CepTor, previously had the same position with Osiris Therapeutics, Inc. Dr. Barton was at Bio-Technology General Corporation (BTGC-NASDAQ) where he was Senior Vice President and Chief Medical Officer.
Dr. Barton received his MD and Ph.D.
from Pennsylvania State University, and he completed his residency in Internal Medicine at Albany Medical College Hospital and his residency in Neurology at Cornell University New York Hospital.
Ehemalige bekannte Positionen von Norman W. Barton
| Unternehmen | Position | Ende |
|---|---|---|
Ceptor Corp. (Maryland)
 Ceptor Corp. (Maryland) Pharmaceuticals: MajorHealth Technology CepTor Corp. develops and provides therapeutic products for neuro mascular and neuro degenerative diseases. The firm's technology includes the development of products for multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, and amyotrophic lateral sclerosis diseases. The company was founded in 1986 and is headquartered in Hunt Valley, MD. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 |
| OSIRIS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2004 |
| SAVIENT PHARMACEUTICALS INC | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2002 |
| SHIRE | Corporate Officer/Principal | - |
Ausbildung von Norman W. Barton
| University of Pennsylvania | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Ceptor Corp. (Maryland)
Ceptor Corp. (Maryland) Pharmaceuticals: MajorHealth Technology CepTor Corp. develops and provides therapeutic products for neuro mascular and neuro degenerative diseases. The firm's technology includes the development of products for multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, and amyotrophic lateral sclerosis diseases. The company was founded in 1986 and is headquartered in Hunt Valley, MD. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |